$410.50 general Payment -- Novartis Pharmaceuticals to Dr. Rachel Parker

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Novartis Pharmaceuticals made a $410.50 general payment to Rachel Parker, a Dermatology specialist in City, MO. The payment was associated with Keytruda. The payment of $410.50 was made by Novartis Pharmaceuticals to Dr. Rachel Parker, a dermatologist. This payment was for services other than consulting, specifically related to the drug Keytruda. The payment occurred on January 18, 2026, in Missouri.

Patient Guidance: What This Payment Means for You

This payment information is for transparency and does not necessarily indicate endorsement or a direct impact on your care. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments to dermatologists for services related to oncology drugs can vary widely depending on the nature of the service provided.

Regulatory Context: Sunshine Act Requirements

This record is part of the CMS Open Payments program, designed to increase transparency around financial relationships between drug/device manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharmaceutical-payments
• physician-compensation
• dermatology
• oncology-drugs
• cms-open-payments
• novartis

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $410.50 payment for?

This was a general payment of $410.50 from Novartis Pharmaceuticals to Rachel Parker, categorized as "Compensation for services other than consulting". It was associated with Keytruda. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Rachel Parker accept pharmaceutical money?

Yes, Rachel Parker received this $410.50 payment from Novartis Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Rachel Parker's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $410.50 should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Dermatology?

To compare this payment against Dermatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Dermatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Rachel Parker's relationship with Novartis Pharmaceuticals?

The payment amount is relatively small, suggesting a specific service or consultation. This $410.50 general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Dermatology?

The payment type is 'general', indicating it's not for research or speaking engagements.

What should patients do after learning about this payment?

This payment information is for transparency and does not necessarily indicate endorsement or a direct impact on your care.

What else should I know about this general payment?

The drug associated, Keytruda, is a significant oncology drug, though the payment is to a dermatologist.

Related Reports

• View Dr. Rachel Parker's full payment report
• Novartis Pharmaceuticals full spending report
• Browse all Dermatology payments
• Browse all payments in Missouri
• Search for other payments